检索结果-南通市图书馆

Comparative analysis of chemical profiles of Radix Astragali between ultrafine granular powder and sliced traditional material

引用

Medicinal Plant Biology 2022年第1期1卷 24-30页

作者： Liang Cao Mei Wang Jianping Zhao Li-Hua Peng Jin-Le Cheng Shi Qiu Ikhlas A.Khan Xing-Cong Li National Center for Natural Products Research School of PharmacyThe University of MississippiUniversityMississippi 38677USA Natural Products Utilization Research Unit Agricultural Research ServiceUnited States Department of AgricultureUniversityMississippi 38677USA Key Laboratory of Technologies and Applications of Ultrafine Granular Powder of Herbal Medicine State Administration of Traditional Chinese MedicineZhongshan Zhongzhi Pharmaceutical Group Co.Ltd.Zhongshan 528437P.R.China Hunan Provincial Key Laboratory of Dong Medicine Hunan University of MedicineHuaihua 41800P.R.China

Radix Astragali,one of the most popular herbs in traditional Chinese medicine(TCM),is used to strengthen the immune system,protect liver function,fight bacteria and viruses,and treat diabetes,heart failure and seasonal *** recent years,a new form of Radix Astragali material processed by cell wall disrupting technology,namely ultrafine granular powder(UGP)has been introduced into the *** order to determine chemical consistency and homogeneity of the UGP material prepared from sliced traditional materials(TM)of Radix Astragali,multiple batches of the UGP and TM samples derived from Astragalus membranaceus *** were analyzed by UHPLC/DAD-MS using isoflavones and triterpenoid glycosides as marker *** results demonstrated that the chemical profiles of UGP was identical or similar to that of TM,but UGP was highly homogeneous in terms of marker compound contents as assessed,e.g.,by the relative standard deviation values of the nine marker compounds in the range of 8.55%−43.80%for TM2 compared against 1.70%−8.38%for *** component preparation and 1H NMR analyses indicated that TM4 and its corresponding UGP4 produced similar polysaccharides,but the later had approximately two-fold dissolution rate of the polysaccharides when compared to the former(yield 7.22±0.35%vs 3.39±0.20%).This study confirms that UGP of Radix Astragali is chemically consistent and homogenous,supporting its use as a promising material in TCM prescriptions.

关键词： chemical deviation identical

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A paratlei mechanism underlying frizzle in domestic chickens

引用

Journal of Molecular cell Biology 2018年第6期10卷 589-591页

作者： Xing Guo Yan-Qing Li Ming-Shan Wang Zhi-Bin Wang Quan Zhang Yong Shao Run-Shen Jiang Sheng Wang Chen-Dong Ma Robert W.Murphy Guang-Qin Wang Jing Dong Li Zhang Dong-Dong Wu Bing-Wang Du Min-Sheng Peng Ya-Ping Zhang State Key Laboratory of Genetic Resources and Evolution and Yunnan Laboratory of Molecular Biology of Domestic Animals Kunmin8 Institute of ZoologyChinese Academy of SciencesKunming 650223 China College of Agricultural Guangdong Ocean UniversityZhanjiang 524088China College of Animal Science and Technology Anhui Agricultural UniversityHefei 230036 China Laboratory of Animal Genetics Breeding and ReproductionMinistry of Agriculture of ChinaNational Engineering Laboratory for Animal BreedingCollege of Animal Science and TechnologyChina Agricultural UniversityBeijing 100193 China Centre for Biodiversity and Conservation Biology Royal Ontario MuseumTorontoM5S2C6Canada 6Jinsheng Animal Husbandry Technology Co. ltd Zhanjiang 524025China Kunming College of Life Science University of Chinese Academy of SciencesKunming 650204China Center for Excellence in Animal Evolution and Genetics Chinese Academy of Sciences Kunming 650223China State Key Laboratory for Conservation and Utilization of Bio-resources Yunnan University Kunming 650091China

Dear Editor,The feather,a highly keratinized tissue with variations in the shape,distribution,pigmentation,and structure,is an attractive topic in developmental and evolutionary biology (Boer et al.,2017).

关键词： evolutionary biology domestic chickens

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy,safety and pharmacokinetics of Unecritinib(TQ-B3101)for patients with ROS1 positive advanced non-small cell lung cancer:a Phase I/II Trial

引用

Signal Transduction and Targeted therapy 2023年第7期8卷 3536-3546页

作者： Shun Lu Hongming Pan Lin Wu Yu Yao Jianxing He Yan Wang Xiuwen Wang Yong Fang Zhen Zhou Xicheng Wang Xiuyu Cai Yan Yu Zhiyong Ma Xuhong Min Zhixiong Yang Lejie Cao Huaping Yang Yongqian Shu Wu Zhuang Shundong Cang Jian Fang Kai Li Zhuang Yu Jiuwei Cui Yang Zhang Man Li Xinxuan Wen Jie Zhang Weidong Li Jianhua Shi Xingxiang Xu Diansheng Zhong Tao Wang Jiajia Zhu Department of Medical Oncology Shanghai Chest HospitalSchool of MedicineShanghai Jiao Tong University200030 ShanghaiChina Department of Medical Oncology Sir Run Run Shaw HospitalZhejiang University310016 HangzhouChina Department of Thoracic Medical Oncology The Affiliated Cancer Hospital of Xiangya School of MedicineCentral South University(Hunan Cancer Hospital)410031 ChangshaChina Department of Medical Oncology The First Affiliated Hospital of Xi’an Jiaotong University710061 XianChina Department of Thoracic Surgery The First Affiliated Hospital of Guangzhou Medical University510120 GuangzhouChina Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical College100021 BeijingChina Department of Oncology Qilu Hospital of Shandong University250012 JinanChina Department of Oncology The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University510699 GuangzhouChina Department of Medical Oncology Sun Yat-sen University Cancer Center510060 GuangzhouChina Department of Respiratory Medicine Harbin Medical University Cancer Hospital150081 HarbinChina Department of Medical Oncology Henan Tumor Hospital450003 ZhengzhouChina Department of Oncology Radiotherapy Anhui Chest Hospital230022 HefeiChina Department of Cancer Center Affiliated Hospital of Guangdong Medical University524000 ZhanjiangChina Department of Respiratory Medicine The First Affiliated Hospital of the University of Science and Technology of ChinaAnhui Provincial Hospital230031 HefeiChina Department of Respiratory and Critical Care Medicine Xiangya Hospital Central South University410008 ChangshaChina Department of Cancer Center Jiangsu Province Hospital210029 NanjingChina Department of Thoracic Oncology Fujian Cancer Hospital and Fujian Medical University Cancer Hospital350014 FuzhouChina Department of Medical Oncology Henan Province People’s Hospital450003 ZhengzhouCh

This phase I/II trial characterized the tolerability,safety,and antitumor activities of unecritinib,a novel derivative of crizotinib and a multi-tyrosine kinase inhibitor targeting ROS1,ALK,and c-MET,in advanced tumors and ROS1 inhibitor-naive advanced or metastatic non-small cell lung cancer(NSCLC)harboring ROS1 *** patients received unecritinib 100,200.

关键词： patients lung cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study

引用

Cancer Communications 2021年第11期41卷 1173-1182页

作者： Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen Department of Gastrointestinal Oncology Key Laboratory of Cancinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital&InstituteBeijing 100142P.R.China Department of Gastrointestinal Oncology Affiliated Zhongshan Hospital of Fudan UniversityShanghai 200032P.R.China Department of Oncology Nanjing Drum Tower Hospitalthe Affiliated Hospital of Nanjing University Medical SchoolNanjingJiangsu 210008P.R.China Department of Oncology Weihai Municipal HospitalWeihaiShandong 264299P.R.China Department of Oncology Anhui Provincial Cancer HospitalHefeiAnhui 230031P.R.China Department of Oncology The First Affiliated Hospital of Xinxiang Medical CollegeXinxiangHenan 453100P.R.China Department of Oncology Subei People’s HospitalYangzhouJiangsu 225009P.R.China Department of Abdominal Oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China Department of Gastrointestinal Oncology Henan Cancer HospitalZhengzhouHenan 450003P.R.China Department of Oncology Linyi Cancer HospitalLinyiShandong 276002P.R.China Department of Oncology The First Affiliated Hospital of Anhui Medical UniversityHefeiAnhui 230022P.R.China Department of Oncology Jiangsu Cancer HospitalNanjingJiangsu 210009P.R.China Department of Oncology The Fifth Medical Center of PLA General HospitalBeijing 100039P.R.China Department of Oncology The First Affiliated Hospital of ZhengzhouZhengzhouHenan 450099P.R.China Department of Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Oncology Yantai Yuhuangding HospitalYantaiShandong 264099P.R.China Department of Oncology The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShanxi 710061P.R.China Department of Oncology Jinan Central HospitalJinanShandong 250013P.R.China Department of Oncology Weifang People’s HospitalWeifangShandong 261041P.R.China Department of Oncology Peking Union Medical College HospitalBeijing 100005P.R.China Department of Oncology Xuzhou Central

Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical ***,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative ***,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction ***:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 *** primary endpoint was the objective response rate(ORR)assessed by an independent review *** endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and ***:Of 179 patients screened,125 were eligible and received RC48 *** ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),*** most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not ***:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy.

关键词： antibody-drug conjugate gastric cancer HER2-overexpressing phase II clinical trial RC48 third-line therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial

引用

Cancer Communications 2021年第9期41卷 889-903页

作者： Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021P.R.China Department of Oncology Yibin Second People’s HospitalYibinSichuan 644000P.R.China Department of Oncology Liuzhou People’s HospitalLiuzhouGuangxi 545006P.R.China Department of Thoracic Oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China Oncology Department the First Affiliated Hospital of Bengbu Medical CollegeBengbuAnhui 233030P.R.China Department of Oncology the First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouGuangdong 510030P.R.China Department of Internal medicine Linyi Cancer HospitalLinyiShandong 276002P.R.China Department of Thoracic Surgery the Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhouGuangdong 510095P.R.China Department of Internal Medicine-Oncology/Department of thoracic oncology Henan Chest HospitalZhengzhouHenan 450003P.R.China The Second Department of Radiotherapy Wuwei Cancer Hospital of Gansu ProvinceWuweiGansu 730000P.R.China Department of Oncology the People’s Hospital of Jiangsu ProvinceNanjingJiangsu 210000P.R.China Respiratory Medicine Department Shanghai East HospitalShanghai 200120P.R.China The Second Department of Internal Medicine-Oncology Xuzhou Central HospitalXuzhouJiangsu 221009P.R.China Oncology Department Tangshan People’s HospitalTangshanHebei 063001P.R.China Respiratory Medicine Department West China Hospital of Sichuan UniversityChengduSichuan 610041P.R.China Thoracic Surgery the Second Affiliated Hospital of Shantou University Medical CollegeShantouGuangdong 515051P.R.China Internal Medicine-Oncology Hunan Cancer HospitalChangshaHunan 410013P.R.China Department of Oncology Xiangyang Central HospitalXiangyangHubei 441021P.R.China Respiratory Department Lishui Central HospitalLishuiZ

Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or *** primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and *** study was registered in Clinical ***(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)*** of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)*** responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,*** stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY010

关键词： anti-angiogenesis anti-VEGF monoclonal antibody avastin bevacizumab biosimilar nonsmall cell lung cancer LY01008 vascular endothelial growth factor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：